Show simple item record

dc.contributor.authorEkanayake Weeramange, C
dc.contributor.authorLiu, Z
dc.contributor.authorHartel, G
dc.contributor.authorLi, Y
dc.contributor.authorVasani, S
dc.contributor.authorLangton-Lockton, J
dc.contributor.authorKenny, L
dc.contributor.authorMorris, L
dc.contributor.authorFrazer, I
dc.contributor.authorTang, KD
dc.contributor.authorPunyadeera, C
dc.date.accessioned2021-11-17T05:11:22Z
dc.date.available2021-11-17T05:11:22Z
dc.date.issued2021
dc.identifier.issn1525-1578en_US
dc.identifier.doi10.1016/j.jmoldx.2021.07.005en_US
dc.identifier.urihttp://hdl.handle.net/10072/410178
dc.description.abstractHigh-risk human papillomavirus (HR-HPV) infection is a major risk factor of head and neck cancers (HNCs). Despite the rising prevalence of HPV-driven HNC (HPV-HNC), biomarkers for detection, prognostication, and disease monitoring are lacking. To evaluate the capacity of salivary HR-HPV DNA as a biomarker of HPV-HNC, the salivary HR-HPV statuses of 491 and 10 patients with primary and recurrent HNC, respectively, were determined at diagnosis, using quantitative real-time PCR and MassARRAY. Tumor cyclin-dependent kinase inhibitor 2A (p16) expression was determined by IHC analysis. Patients with oropharyngeal cancer (OPC) (n = 215) were followed up for ≤5 years. Survival characteristics were evaluated in terms of event-free and cause-specific survival. Of the primary-HNC cohort, 43.2% were positive for salivary HR-HPV DNA, with most having OPC. Salivary HR-HPV DNA was detected in 81.4% of tumor p16–positive OPC patients at diagnosis. Prognosis in salivary HR-HPV–positive OPC patients was favorable compared with that in salivary HR-HPV–negative patients (event-free survival, hazard ratio = 0.42 [95% CI, 0.21–0.81, P = 0.010]; cause-specific survival, hazard ratio = 0.39 [95% CI, 0.18–0.86, P = 0.019]). In the recurrent-HNC cohort, salivary HR-HPV DNA was detected in 83.3% of those who previously had tumor p16–positive HNC. These findings indicate that this liquid biopsy–based, noninvasive biomarker can play an essential role in the detection and management of HPV-HNC.en_US
dc.description.peerreviewedYesen_US
dc.languageengen_US
dc.publisherElsevier BVen_US
dc.relation.ispartofpagefrom1334en_US
dc.relation.ispartofpageto1342en_US
dc.relation.ispartofissue10en_US
dc.relation.ispartofjournalJournal of Molecular Diagnosticsen_US
dc.relation.ispartofvolume23en_US
dc.titleSalivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancersen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationEkanayake Weeramange, C; Liu, Z; Hartel, G; Li, Y; Vasani, S; Langton-Lockton, J; Kenny, L; Morris, L; Frazer, I; Tang, KD; Punyadeera, C, Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers, Journal of Molecular Diagnostics, 2021, 23 (10), pp. 1334-1342en_US
dcterms.dateAccepted2021-07-08
dc.date.updated2021-11-17T05:10:47Z
gro.hasfulltextNo Full Text
gro.griffith.authorPunyadeera, Chamindie


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record